did tirzepatide get discontinued Adults with obesity who discontinue semaglutide, achieve minimal weight loss Compounded GLP-1 - Semaglutide &

Factors That Speed Up or Slow Down Your Results Consistent dose escalation directly impacts speed of weight lossskipping doses or delaying increases slows progress

Conclusions Three years of treatment with tirzepatide in persons with obesity and prediabetes resulted in substantial and sustained weight reduction and a markedly lower risk of progression to type 2 diabetes than that with placebo

Tirzepatide goes a step further by also targeting glucose-dependent insulinotropic polypeptide (GIP) another gut-derived incretin hormone with complementary but distinct effects

What to Expect by Week 2-3 Most patients move into a more stable phase by week 2, with nausea fading and appetite suppression becoming consistent and predictable

These include: Nausea (affecting 2040% of patients initially) Vomiting and diarrhoea Constipation Abdominal discomfort or bloating Reduced appetite These symptoms are usually mild to moderate and tend to diminish over several weeks as the body adjusts to the medication